<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordOutput xmlns:ns2="local" id="8012"><TitleDisplay>Safety, Follow-up on Children and Adolescents With Type 1 Diabetes Treated With Insulin Detemir. An Extension to Trial NN304-1689</TitleDisplay><TitleOfficial>A 52-Week, Multinational, Multicenter, Open-Labeled, Extension Trial of Insulin Detemir in Children and Adolescents 3 to 17 Years With Type 1 Diabetes on a Basal-Bolus Regimen With Insulin Aspart as Bolus Insulin</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">2006-002478-23</Identifier><Identifier type="Organisational Study">NN304-1690</Identifier><Identifier type="NCT">NCT00623194</Identifier></Identifiers><Indications><Indication id="836">Insulin dependent diabetes</Indication></Indications><BiomarkerNames><BiomarkerName id="118" role="Therapeutic effect marker" type="Genomic;Proteomic">Albumin</BiomarkerName><BiomarkerName id="125" role="Therapeutic effect marker" type="Cellular">Leukocyte count</BiomarkerName><BiomarkerName id="154" role="Therapeutic effect marker" type="Genomic;Proteomic">Lactate dehydrogenase</BiomarkerName><BiomarkerName id="289" role="Therapeutic effect marker" type="Biochemical">Hemoglobin A, glycosylated</BiomarkerName><BiomarkerName id="1211" role="Therapeutic effect marker" type="Genomic;Proteomic">Alanine transaminase</BiomarkerName><BiomarkerName id="1236" role="Therapeutic effect marker" type="Biochemical">Hemoglobin</BiomarkerName><BiomarkerName id="1735" role="Therapeutic effect marker" type="Biochemical">Glucose</BiomarkerName><BiomarkerName id="2054" role="Therapeutic effect marker" type="Cellular">Blood platelets</BiomarkerName><BiomarkerName id="2098" role="Therapeutic effect marker" type="Biochemical">Potassium</BiomarkerName><BiomarkerName id="2626" role="Therapeutic effect marker" type="Biochemical">Total protein</BiomarkerName><BiomarkerName id="2662" role="Therapeutic effect marker" type="Biochemical">Sodium</BiomarkerName><BiomarkerName id="5016" role="Therapeutic effect marker" type="Biochemical">Creatine</BiomarkerName><BiomarkerName id="28899" role="Therapeutic effect marker" type="Genomic;Proteomic">Alkaline phosphatase</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>insulin aspart</Name><Drug id="10411">insulin aspart</Drug></Intervention><Intervention type="InterventionPrimary"><Name>insulin detemir</Name><Drug id="17426">insulin detemir</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="10411">insulin aspart</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="18614">Novo Nordisk A/S</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="17426">insulin detemir</Drug><IndicationsPioneer></IndicationsPioneer><Companies><Company><Company id="18614">Novo Nordisk A/S</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="10411" type="Drug"><TargetEntity id="134086" type="siDrug">Insulin aspart</TargetEntity></SourceEntity><SourceEntity id="17426" type="Drug"><TargetEntity id="239855" type="siDrug">Insulin detemir</TargetEntity></SourceEntity><SourceEntity id="18614" type="Company"><TargetEntity id="4295865996" type="organizationId">Novo Nordisk A/S</TargetEntity></SourceEntity><SourceEntity id="836" type="ciIndication"><TargetEntity id="E10" type="ICD10"></TargetEntity><TargetEntity id="10067584" type="MEDDRA"></TargetEntity><TargetEntity id="D003922" type="MeSH"></TargetEntity><TargetEntity id="-686743471" type="omicsDisease"></TargetEntity><TargetEntity id="507" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="400" type="Action"><TargetEntity id="609" type="Mechanism">Insulin Secretagogues</TargetEntity><TargetEntity id="1034" type="Mechanism">Insulin Receptor Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>32</NumberOfSites><CompaniesSponsor><Company id="18614">Novo Nordisk A/S</Company></CompaniesSponsor><CompaniesCollaborator></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="23014">Insulin ligand</Action><Action id="400">Insulin receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="38211">Human insulin fast acting product</Class><Class id="38212">Human insulin intermediate acting product</Class><Class id="399">Hypoglycemic agent</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="740">Infusion</Technology><Technology id="1646">Injectable controlled release formulation</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="80">Peptide</Technology><Technology id="85">Protein recombinant</Technology><Technology id="662">Quick release formulation</Technology><Technology id="746">Solution</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="745">Suspension</Technology></Technologies><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>146</PatientCountEnrollment><DateStart>2008-02-29T00:00:00Z</DateStart><DateEnd type="actual">2009-09-01T00:00:00Z</DateEnd><DateChangeLast>2018-05-26T09:34:33Z</DateChangeLast><DateAdded>2008-02-28T11:23:35Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Novo Nordisk A/S</Affiliation><Name>Global Clinical Registry (GCR, 1452)</Name></Contact><Contact type="Scientific contact"><Affiliation>Novo Nordisk A/S</Affiliation><Email>clinicaltrials@novonordisk.com</Email><Name>Jens Larsen</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Informed Consent obtained before any trial-related activities. (Trial-related
             activities are any procedure that would not have been performed during normal
             management of the subject). The parents or legal representative of the subject must
             sign and date the Informed Consent Form&lt;/li&gt;&lt;li&gt;Finalized 52 weeks of treatment with&lt;ulink linkType="Drug" linkID="17426"&gt;insulin detemir&lt;/ulink&gt; in trial &lt;ulink linkType="Protocol" linkID="3902"&gt;NN304-1689&lt;/ulink&gt;&lt;/li&gt;&lt;li&gt;Fertile females (girls who have had their first menstrual period) must use adequate
             contraception (barrier methods, contraceptive pills or intrauterine device (IUD)) if
             there is any risk of pregnancy in the opinion of the Investigator. For Denmark and
             France only contraceptive pills or intrauterine device are considered as adequate
             contraceptive methods&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Significant concomitant disease such as endocrine, hepatic, renal, cardiac,
             respiratory, neurological, gastrointestinal, malignant or pancreatic diseases as
             judged by the Investigator&lt;/li&gt;&lt;li&gt;Pregnant or the intention of becoming pregnant&lt;/li&gt;&lt;li&gt;Previous participation in this trial (defined as enrollment)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Insulin detemir-insulin aspart cross-reacting antibodies</Description><Timeframe>Weeks 0, 52 and 104</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Development of insulin detemir specific antibodies and insulin aspart specific antibodies in percent of total antibodies</Description><Timeframe>At 0, 52 and 104 weeks</Timeframe></Measure><Measure><Description>Glycosylated hemoglobin A1c (HbA1c)</Description><Timeframe>At 104 weeks</Timeframe></Measure><Measure><Description>Fasting plasma glucose values</Description><Timeframe>At 104 weeks</Timeframe></Measure><Measure><Description>Hypoglycemic episodes</Description><Timeframe>Weeks 0 to 104 </Timeframe></Measure><Measure><Description>BMI (Body Mass Index)</Description><Timeframe>At 104 weeks</Timeframe></Measure><Measure><Description>SD-score (Z-score) for body weight</Description><Timeframe>At 104 weeks</Timeframe></Measure><Measure><Description>Diabetic ketoacidosis</Description><Timeframe>At 104 weeks</Timeframe></Measure><Measure><Description>Insulin dose</Description><Timeframe>At 104 weeks</Timeframe></Measure><Measure><Description>Albumin serum and total protein serum (g/dl)</Description><Timeframe>At 104 weeks</Timeframe></Measure><Measure><Description>Creatine serum (Umol/l)</Description><Timeframe>At 104 weeks</Timeframe></Measure><Measure><Description>Sodium serum, potassium serum and hemoglobin (mmol/l)</Description><Timeframe>At 104 weeks</Timeframe></Measure><Measure><Description>Alkaline phosphatase serum, alanine aminotransferase serum and lactate dehydrogenase serum (U/l)</Description><Timeframe>At 104 weeks</Timeframe></Measure><Measure><Description>Leukocytes and thrombocytes</Description><Timeframe>At 104 weeks</Timeframe></Measure><Measure><Description>Fundoscopy/fundus photography: Abn; CS = abnormal, clinically significant Abn. NCS = abnormal, not clinically significant</Description><Timeframe>At 52 and 104 weeks</Timeframe></Measure><Measure><Description>Blood pressure</Description><Timeframe>At 104 weeks</Timeframe></Measure><Measure><Description>Vital signs: pulse</Description><Timeframe>At 104 weeks</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This trial was conducted in Europe. The aim of this research was to assess the safety of continuous treatment with  &lt;ulink linkType="Drug" linkID="17426"&gt;insulin detemir&lt;/ulink&gt; following participation in trial &lt;ulink linkType="Protocol" linkID="3902"&gt;NN304-1689&lt;/ulink&gt; (NCT00435019) on antibody development.  &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would receive &lt;ulink linkType="Drug" linkID="17426"&gt;insulin detemir&lt;/ulink&gt; twice daily plus &lt;ulink linkType="Drug" linkID="10411"&gt;insulin aspart&lt;/ulink&gt; at larger meals, doses were adjusted individually. The treatment period was up to 104 weeks.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions></AdverseEventsByInterventions><DoseRouteByInterventions></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Bulgaria"><Sites><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Pleven</Address1><Address3>5800</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Sofia</Address1><Address3>1606</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Varna</Address1><Address3>9010</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Czech Republic"><Sites><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Olomouc</Address1><Address3>77520</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Pardubice</Address1><Address3>53203</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Prague 5</Address1><Address3>15018</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Denmark"><Sites><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Glostrup</Address1><Address3>2600</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Kolding</Address1><Address3>6000</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Odense</Address1><Address3>5000</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Finland"><Sites><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Helsinki</Address1><Address3>00029</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Oulu</Address1><Address3>90029</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Seinäjoki</Address1><Address3>60220</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Turku</Address1><Address3>20100</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="France"><Sites><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Paris</Address1><Address3>75015</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Toulouse</Address1><Address3>31059</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="UK"><Sites><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Aberdeen</Address1><Address3>AB25 2ZG</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Dundee</Address1><Address3>DD1 9SY</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Norfolk</Address1><Address3>NR4 7UY</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Hungary"><Sites><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Budapest</Address1><Address3>1083</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Miskolc</Address1><Address3>3501</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Macedonia, The Former Yugoslav Republic of"><Sites><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Skopje</Address1><Address3>1000</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Poland"><Sites><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Gdansk</Address1><Address3>80-211</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Kielce</Address1><Address3>25-734</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Warszawa</Address1><Address3>01-184</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Russian Federation"><Sites><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Moscow</Address1><Address3>117036</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Moscow</Address1><Address3>119049</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Moscow</Address1><Address3>125373</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Saint-Petersburg</Address1><Address3>193144</Address3><Contacts></Contacts></Site></Sites></SitesByCountry><SitesByCountry country="Turkey"><Sites><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Altunizade-Istanbul</Address1><Address3>34662</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Antalya</Address1><Address3>07059</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Istanbul</Address1><Address3>34093</Address3><Contacts></Contacts></Site><Site><Name>Novo Nordisk Investigational Site</Name><Address1>Izmir</Address1><Address3>35340</Address3><Contacts></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Insulin dependent diabetes</Disease><PatientSegments><PatientSegment><PatientSegment id="7628">Subjects on Treatment of Insulin</PatientSegment><SubSegments><SubSegment id="7632">Subjects on basal-bolus insulin regimen</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00623194</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2006-002478-23</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Insulin dependent diabetes" id="18173"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Insulin dependent diabetes" id="18154">Assessment of anti-drug antibodies</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Insulin dependent diabetes" id="18111"><Endpoint>Assessment of HbA1c Levels</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="18155"><Endpoint>Assessment of Hypoglycemic Episodes</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="18164"><Endpoint>Assessment of Renal Function</Endpoint><SubEndpoints><SubEndpoint disease="Insulin dependent diabetes" id="18166">Urinary albumin excretion/albuminuria</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="18173"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Insulin dependent diabetes" id="18154">Assessment of anti-drug antibodies</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="18206"><Endpoint>Assessment of Insulin Dose</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Insulin dependent diabetes" id="44211"><Endpoint>Glycemic Control Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Insulin dependent diabetes" id="18123">Assessment of fasting blood glucose</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Insulin dependent diabetes" id="16338"><Criterion>Subjects on Treatment of Insulin</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Insulin dependent diabetes" id="13757"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion><SubCriteria><SubCriterion disease="Insulin dependent diabetes" id="13758">Subjects with chronic kidney disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13785"><Criterion>Subjects co-morbid with heart disorders/diseases</Criterion></Exclusion><Exclusion disease="Insulin dependent diabetes" id="13811"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2009-09-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2008-09-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>7.10 Months</EnrollmentPeriod><EnrollmentRate>20.56 Patients/Month</EnrollmentRate><DateFirstReceived>2008-02-14T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-02-28T11:23:35Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialRecordOutput>